Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19, DHSC (published/updated 31st January 2022)

Updated policy reflects tocilizumab is now licensed in the treatment of patients receiving systemic corticosteroids and require supplemental oxygen/mechanical ventilation. Sarilumab (off-label) should continue to be considered where tocilizumab is not available/cannot be used.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news